Understanding the Market | GIANT BIOGENE falls over 6% as collagen restructuring faces controversy; the company's 618 promotional campaign starts off well

GIANT BIOGENE's stock price fell over 6%, down 6.15% as of the time of writing, at HKD 76.35, with a trading volume of HKD 908 million. Huaxi Biologics questioned the research report on the restructured collagen, claiming it contains misleading statements. Nevertheless, Citigroup pointed out that GIANT BIOGENE had a good start during the 618 promotional event, raising the target price to HKD 93.7 and maintaining a "Buy" rating